echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hausen "Erlotinib Hydrochloride Tablets" Approved for Listing

    Hausen "Erlotinib Hydrochloride Tablets" Approved for Listing

    • Last Update: 2021-06-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 31, Hausen's "Erlotinib Hydrochloride Tablets" was approved by the National Medical Products Administration (NMPA), becoming the second domestic generic drug of this variety.


    Erlotinib is the first-generation EGFR inhibitor and was approved by the FDA as early as 2004 for the treatment of locally advanced or metastatic NSCLC after at least one chemotherapy failure.


    Image source: Insight database (https://db.


    At present, in addition to Shanghai Chuangnuo, which is the first imitation approved in China, the Insight database shows that in addition to Hausen, the companies that are currently applying for listing of the drug include Xinlitai, Shandong Kongfu Pharmaceutical, Nanjing Youke, Suzhou Terui, Hunan Kelun and imported generic drugs from India, Dr.


    Image source: Insight database (https://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.